GeneVac-B (recombinant hepatitis B vaccine) / Serum Institute of India - LARVOL DELTA

Hepatitis B Vaccine Nonresponse and Associated Risk Factors: Insights From a Cohort Study. (PubMed, J Trop Med) - "Participants received GeneVac-B, a recombinant hepatitis B vaccine, and 0-, 1-, and 2-month schedule anti-HB levels were measured post-vaccination using a commercial enzyme-linked immunosorbent assay (ELISA) kit (AccuDiag ELISA, Diagnostic Automation/Cortez Diagnostics, Inc., USA) to classify vaccine response...Prior tuberculosis, malaria, measles, smoking, and alcohol use showed no significant impact on the immune response, although recurrent malaria, measles, and smoking were associated with slightly lower mean antibody levels. The study indicates gender and age significantly influence hepatitis B vaccine response, with females and younger individuals demonstrating stronger immunity."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Malaria • Measles • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Immune response to GeneVac-BⓇ (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso. (PubMed, IJID Reg) - "The results showed an excellent immune response to GeneVac-BⓇ in our study population. However, age > 40 and high total cholesterol appear to be factors associated with nonresponse."

Journal • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Are International Units of Anti-HBs Antibodies Always Indicative of Hepatitis B Virus Neutralizing Activity? (PubMed, Vaccines (Basel)) - "The level of anti-HBs antibodies in IUs is not sufficient to assess neutralizing activity. Consequently, (i) an in vitro neutralization assay should be included in the quality control procedures of antibody preparations intended for HB prophylaxis or immunotherapy, and (ii) a greater emphasis should be placed on ensuring that vaccine genotype/subtype matches with that of the circulating HBV."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts (clinicaltrials.gov) - P1/2 | N=75 | Completed | Sponsor: Zagazig University

New P1/2 trial • Dermatology • Hepatitis B • Hepatology • Infectious Disease • Inflammation

[VIRTUAL] HUMORAL IMMUNITY RESPONSES AFTER VACCINATION FOR HEPATITIS B VIRUS IN AUTOGRAFTED PATIENTS: A SINGLE CENTER EXPERIENCE (EHA 2021) - "After a median of 4,3 (0,6–8,5) ys post AHSCT, the recombinant HBV vaccine Genevac-B® (Serum Institute of India Pvt...Although the intervention was offered late post AHSCT and pts had already adequate lymphocytes subpopulations counts at the time of vaccination, the response rates were lower compared to healthy individuals. Our results, in agreement with others, are indicative of a long lasting immune impairment post AHSCT highlighting the necessity of prolonged surveillance and intensified vaccination programs for autografted pts."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Transplantation • CD8